Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

CA67059R1091
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG002CV5Z46
NRX
NurExone Biologic Inc.
GICS: - · SECTOR: EQTY · SUB-SECTOR: -
NAME
NurExone Biologic Inc.
ISIN
CA67059R1091
TICKER
NRX
MIC
XTSX
REUTERS
NRX.V
BLOOMBERG
NRX CN
Fr., 09.08.2024       NurExone
CA67059R1091

NurExone announces promising new data for its ExoPTEN nanodrug, highlighting progress towards commercial-grade manufacturing...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Mi., 17.07.2024       NurExone
CA67059R1091

Minimally Invasive treatment with ExoPTEN showed functional restoration of damaged eyes to healthy levels in animals Minimally Invasive treatment with ExoPTEN showed functional restoration of damaged eyes to healthy levels in animals...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Fr., 28.06.2024       NurExone
CA67059R1091

Prestigious Eye Institute Exploring New Indication for NurExone’s ExoPTEN...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Fr., 21.06.2024       NurExone
CA67059R1091

TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, welcomes Dr. Yona Geffen, as a consultant, to support the Company’s preclinical and clinical activities. Dr. Geffen, who currently serves as Vice Pre...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Di., 04.06.2024       NurExone
CA67059R1091

NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Mi., 29.05.2024       NurExone
CA67059R1091

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Fr., 17.05.2024       NurExone
CA67059R1091

NurExone Welcomes Biopharma Executive Dr. Ram Petter to Drive Strategic Collaborations...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Fr., 07.07.2023       NurExone
CA67059R1091

Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - July 7, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) ("NurExone" or the "Company") is pleased to announce that, effective July 6, 2023, Dr. Gadi Riesenfeld has been appointed to the board of directors of the Company replacing Mr. Ron Mayron, who resigned for personal reasons....
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Fr., 12.05.2023       NurExone
CA67059R1091

Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, announced that it has engaged Litchfield Hills Resea...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Mo., 08.05.2023       NurExone
CA67059R1091

Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 8, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, announces that it has granted an aggregate of 1,145,520 incentive st...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 12.01.2023       NurExone
CA67059R1091

The patent covers NurExone's ExoPTEN drug compositions and treatment methods for Central Nervous System diseaseHaifa, Israel and Calgary, Alberta--(Newsfile Corp. - January 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy"...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Do., 15.12.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - December 15, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) ("we", "our", the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, is pleased to provide the following shareholder letter from Nur...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Do., 08.12.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - December 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it completed its securities for...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Do., 01.12.2022       NurExone
CA67059R1091

Company's analysis indicates the successful achievement of its proprietary loading technology for producing exosome-based therapiesNurExone is providing an updated release to the previously disseminated release from yesterday to replace several sentences and figures that were included in error.Calgary, Alberta--(Newsfile Corp. - December 1, 2022) -...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Mi., 30.11.2022       NurExone
CA67059R1091

Company's analysis indicates the successful achievement of its proprietary loading technology for producing exosome-based therapiesCalgary, Alberta--(Newsfile Corp. - November 30, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoThera...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Fr., 25.11.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has agreed to settle debts in the amoun...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Do., 24.11.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, released a corporate update and reported financial results for the quarter e...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Di., 08.11.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - November 8, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has completed its securities...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Mi., 02.11.2022       NurExone
CA67059R1091

The U.S. Food and Drug Administration (FDA) informed NurExone that it is at the appropriate stage of its product development for a pre-Investigational New Drug (pre-IND) meetingA pre-IND meeting could potentially shorten the regulatory timeline for the launch of NurExone's ExoTherapy into the U.S. market.Calgary, Alberta--(Newsfile Corp. - November...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Mi., 26.10.2022       NurExone
CA67059R1091

Results indicate that the proprietary production process boosts exosome productivity, improving cost-efficiencyCalgary, Alberta--(Newsfile Corp. - October 26, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients wit...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 20.10.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - October 20, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that the Company will be participating in the upcoming 2022 Bio-Europ...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Mi., 12.10.2022       NurExone
CA67059R1091

Both companies will collaborate to improve NurExone's drug development stages, from R&D to Quality AssuranceCompany to host an investor webinar on Thursday, October 20th, 2022 at 11:00 AM ESTCalgary, Alberta and Oxford, United Kingdom--(Newsfile Corp. - October 12, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExon...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Mi., 12.10.2022       NurExone
CA67059R1091

Both companies will collaborate to improve NurExone's drug development stages, from R&D to Quality AssuranceCompany to host an investor webinar on Thursday, October 20th, 2022 at 11:00 AM ESTCalgary, Alberta and Oxford, United Kingdom--(Newsfile Corp. - October 12, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExon...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Di., 04.10.2022       NurExone
CA67059R1091

Results show a significant increase in effectiveness of NurExone's therapeutic compounds in inhibition of PTEN expressionCalgary, Alberta--(Newsfile Corp. - October 4, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for pat...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Mo., 03.10.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - October 3, 2022) - Further to our news release of September 1, 2022, NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Mi., 07.09.2022       NurExone
CA67059R1091

Calgary, Alberta, Canada and Dresden, Germany--(Newsfile Corp. - September 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is pleased to announce that the Company has entered into a letter of...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Do., 01.09.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - September 1, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, announced today that it agrees to offer 170,195 common shares...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Do., 25.08.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - August 25, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients suffering from traumatic spinal cord injuries, released a business update and reported financial results for the q...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Di., 09.08.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - August 9, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, released excerpts from a letter uploaded to Sedar today from Mr. Jay Richardson, For...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Mo., 25.07.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - July 25, 2022) - NurExone Biologic Inc. (TSXV: NRX) ("NurExone" or the "Company"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other Central Nervous System ("CNS") indications, is pleased to announce that it will showcase a poster pres...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink
Di., 19.07.2022       NurExone
CA67059R1091

Calgary, Alberta--(Newsfile Corp. - July 19, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other Central Nervous System ("CNS") indications, announced the si...
Zur Nachricht
NurExone
Charts & Research Termsheets Terminal
Permalink